Accessibility Statement Skip Navigation
  • Resources
  • Data Privacy
  • Contact Us
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
    • Overview
    • Distribution by PR Newswire
    • Guaranteed Paid Placement
    • Cision Media Monitoring
    • Multichannel Amplification
    • All Products
  • Contact
    • General Inquiries
    • Request a Demo
    • Partnerships
    • Media Inquiries
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • All Multimedia

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Accessories
      • Computer Hardware
      • Computer Networks
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High-Tech Security
      • Internet Technology
      • Nanotechnology
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art, Culture & Design
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Projections or Forecasts
      • Financing Agreements
      • Insurance
      • Investment Options
      • Joint Ventures
      • Mutual Funds
      • Offerings
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing/marketing agreements
      • New Products & Services
      • Obituary
      • Outsourcing Businesses
      • Overseas Real Estate (Non-US)
      • Personnel Announcements
      • Residential Real Estate
      • Small-Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Accessories
      • Computer Electronics
      • Computer Hardware
      • Computer Networks
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Design Automation
      • Financial Technology
      • Mobile Devices/Apps
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Natural Gas Utilities
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Computer Accessories
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Computer Accessories
      • Computer Networks
      • Mobile Devices/Apps
      • Telecommunications
      • Telecommunications Carriers & Services
      • Telecommunications Equipment
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wine & Spirits
      • Beverages
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art, Culture & Design
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infectious Disease Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental Products & Services
      • European Government
      • Natural Disasters
      • Not-for-Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Children-related news
      • Disabled Persons
      • Diversity, Equity & Inclusion
      • Hispanic-oriented news
      • LGBTQ+
      • Religion
      • Senior Citizens
      • Veterans
      • Women-Related news
      • View All People & Culture

  • Overview
  • Distribution by PR Newswire
  • Guaranteed Paid Placement
  • Cision Media Monitoring
  • Multichannel Amplification
  • All Products
  • General Inquiries
  • Request a Demo
  • Partnerships
  • Media Inquiries
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring Home
  • Send a Release
    • Chat

    • ALL CONTACT INFO
    • Contact Us


  • News Releases
  • Send a Release
  • Data Privacy
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • News Releases
  • Send a Release
  • Data Privacy
  • Overview
  • Distribution by PR Newswire
  • Guaranteed Paid Placement
  • Cision Media Monitoring
  • Cision IR
  • SocialBoost
  • All Products
  • News Releases
  • Send a Release
  • Data Privacy
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • News Releases
  • Send a Release
  • Data Privacy

Shingles Awareness Week 2025: Shingles increases risk for heart attack and stroke; the disease also increases risk for hospitalisation more than thrice in people with diabetes

(PRNewsfoto/GSK)

News provided by

GSK

26 Feb, 2025, 14:45 CST

Share this article

Share toX

Share this article

Share toX

  • People who have had shingles are at a 59% higher risk for heart attack and at a 35% higher risk for stroke compared to those who have not had shingles.
  • Adults aged 50 years or over are at high risk for shingles due to age-related decline in immunity and the risk further increases amongst those with underlying chronic health conditions such as chronic obstructive pulmonary disease (COPD), cardiovascular disease, and diabetes.
  • If people with diabetes contract shingles, they are at least three times more likely to be hospitalised due to shingles compared to those without diabetes.

SINGAPORE, Feb. 26, 2025 /PRNewswire/ -- A study has reported that people who have had shingles, also known as herpes zoster, are at a significantly higher risk of heart attack (+59%) and stroke (+35%) compared to those who have not had shingles.[1] In another study, it has been reported that people with diabetes are at least three times more likely to be hospitalised due to shingles compared to those without diabetes.[2]

Continue Reading
Businessman Mr. Lionel L. of Singapore had shingles at the age of 56 (GSK).
Businessman Mr. Lionel L. of Singapore had shingles at the age of 56 (GSK).

Shingles is a viral infection caused by the reactivation of the varicella-zoster virus — the same virus that causes chickenpox.[3] With age-related decline in immunity, people aged 50 years or over are at a higher risk for contracting shingles compared to those who are younger.[4],[5]

The risk for shingles further increases amongst people with underlying chronic health conditions, such as chronic obstructive pulmonary disease (COPD), cardiovascular diseases, and diabetes.[6]

In Singapore, around nine out of ten adults aged 50 years or over have had chickenpox[7] and 85% of the country's older population live with at least one chronic health condition, while 45% have been diagnosed with three or more.[8]

The five most reported chronic health conditions amongst older adults in Singapore were: high blood pressure or hypertension; high blood cholesterol or lipids; joint pain, arthritis, or nerve pain; high blood sugar or diabetes; and renal/kidney or urinary tract ailments. [9]

Dr. Sue-Anne Ee Shiow Toh, Endocrinologist and Co-Founder and Chief Executive Officer at NOVI Health, shared with GSK that from a clinical perspective, the impact of shingles on people with chronic health conditions or comorbidities can be severe.

'Ageing patients with comorbidities are more susceptible to infections, and when shingles occurs, it can lead to prolonged healing times, increased nerve pain, and even heightened cardiovascular risks,' shared Dr. Toh.

People with diabetes, for example, are at a 30% higher risk of getting shingles compared to those who do not have diabetes.[10] If they do contract shingles, they are at least three times more likely to be hospitalised due to shingles compared to those without diabetes.[11]

Mr. Satyaprakash Tiwari, Executive Director, Diabetes Singapore, shared with GSK: 'Diabetes is a chronic condition that already presents many health challenges. The additional risk of shingles and its complications is something that many people with diabetes may not be aware of.'

During this year's Shingles Awareness Week, GSK has partnered with Diabetes Singapore to raise awareness about the risks of shingles for people with diabetes and launched a campaign to share experiences of people who have had shingles. One such experience is that of Mr. Lionel L., a businessman from Singapore, who contracted the disease at the age of 56.

Raakhi Sippy, General Manager of GSK Singapore, commented: 'Many people are unaware of the risks associated with shingles, such as increased risk of heart attack, stroke, and hospitalisation. Raising awareness, especially amongst Singaporeans aged 50 years or over, is a key step towards protecting them from shingles and related complications.'

'Given these risks, it is important that individuals over 50, particularly those with comorbidities, are informed about the available preventive measures against shingles,' Dr. Toh added.

For more information on shingles and the Shingles Awareness Week campaign, visit https://www.stopshingles.com.

About Shingles Awareness Week 

Shingles Awareness Week (23 February – 1 March 2025) is an annual global awareness week dedicated to improving public knowledge about the risks and severity of shingles. In collaboration with the International Federation on Ageing (IFA), GSK has set up the Shingles Awareness Week to encourage informed conversations between adults, particularly those aged 50 years or over, and their healthcare professionals about shingles.

About GSK Singapore

GSK is a global biopharma company with the ambition and purpose to unite science, technology and talent to get ahead of disease together.

With the aim to positively impact the health of 2.5 billion people at the end of the decade, GSK prioritises innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease. At the heart of this is the company's R&D focus on the science of the immune system, human genetics and advanced technologies, and world-leading capabilities in vaccines and medicines development.

Singapore is the hub for GSK's Global General Medicines (GM) and the Greater China and Intercontinental (GCI) and Emerging Markets (EM) regions. It houses three manufacturing sites (Jurong, Quality Road, Tuas), comprising two for medicines and one for vaccines. GSK's business in Singapore is spread across four sites – the three manufacturing sites and its corporate and commercial office (GSK Asia House).    

For more information on GSK please go to https://www.gsk.com/en-gb/      

[1] Kim, M. C., Yun, S. C., Lee, H. B., Lee, P. H., Lee, S. W., Choi, S. H., Kim, Y. S., Woo, J. H., Kim, S. H., & Kwon, S. U. (2017). Herpes Zoster Increases the Risk of Stroke and Myocardial Infarction. Journal of the American College of Cardiology, 70(2), 295–296. https://doi.org/10.1016/j.jacc.2017.05.015

[2] Giorda, C. B., Picariello, R., Tartaglino, B., Nada, E., Romeo, F., Costa, G., & Gnavi, R. (2024). Hospitalisation for herpes zoster in people with and without diabetes: A 10-year-observational study. Diabetes research and clinical practice, 210, 111603. https://doi.org/10.1016/j.diabres.2024.111603

[3] Herpes zoster (shingles). HealthHub. (n.d.). https://www.healthhub.sg/a-z/diseases-and-conditions/herpes_zoster

[4] Shiraki, K., Toyama, N., Shiraki, A., Yajima, M., & Miyazaki Dermatologist Society (2018). Age-dependent trigeminal and female-specific lumbosacral increase in herpes zoster distribution in the elderly. Journal of dermatological science, 90(2), 166–171. https://doi.org/10.1016/j.jdermsci.2018.01.009.

[5] Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis. 2004 Jan;4(1):26-33. doi: 10.1016/s1473-3099(03)00857-0. PMID: 14720565.

[6] Steinmann M, Lampe D, Grosser J, Schmidt J, Hohoff ML, Fischer A, Greiner W. Risk factors for herpes zoster infections: a systematic review and meta-analysis unveiling common trends and heterogeneity patterns. Infection. 2024 Jun;52(3):1009-1026. doi: 10.1007/s15010-023-02156-y. Epub 2024 Jan 18. PMID: 38236326; PMCID: PMC11142967.

[7] Fatha N, et al. Int J Infect Dis. 2014;22:73-77.

[8] Chan, A., Malhotra, R., Visaria, A., Sung, P., Siok Seng, B. J., Ching, & Tan, Y. W. (2020). Transitions in health, employment, social engagement and intergenerational Transfers in Singapore Study (THE SIGNS Study) – II: Cross-Sectional and Longitudinal analyses of Key aspects of Successful Ageing. Centre for Ageing Research and Education, Duke-NUS Medical School. https://www.duke-nus.edu.sg/docs/librariesprovider3/publications-docs/the-signs-study---ii-report-(revised).pdf?sfvrsn=b391ced0_0.

[9] Chan, A., Malhotra, R., Visaria, A., Sung, P., Siok Seng, B. J., Ching, & Tan, Y. W. (2020). Transitions in health, employment, social engagement and intergenerational Transfers in Singapore Study (THE SIGNS Study) – II: Cross-Sectional and Longitudinal analyses of Key aspects of Successful Ageing. Centre for Ageing Research and Education, Duke-NUS Medical School. https://www.duke-nus.edu.sg/docs/librariesprovider3/publications-docs/the-signs-study---ii-report-(revised).pdf?sfvrsn=b391ced0_0.

[10] Papagianni, M., Metallidis, S., & Tziomalos, K. (2018). Herpes Zoster and Diabetes Mellitus: A Review. Diabetes therapy : research, treatment and education of diabetes and related disorders, 9(2), 545–550. https://doi.org/10.1007/s13300-018-0394-4

[11] Giorda, C. B., Picariello, R., Tartaglino, B., Nada, E., Romeo, F., Costa, G., & Gnavi, R. (2024). Hospitalisation for herpes zoster in people with and without diabetes: A 10-year-observational study. Diabetes research and clinical practice, 210, 111603. https://doi.org/10.1016/j.diabres.2024.111603

SOURCE GSK

Modal title

Also from this source

GSK's Omjjara (momelotinib) approved in Singapore as the first treatment indicated for myelofibrosis patients with anaemia

GSK's Omjjara (momelotinib) approved in Singapore as the first treatment indicated for myelofibrosis patients with anaemia

GSK Singapore today announced that Omjjara (momelotinib) has been locally approved for treatment of disease-related splenomegaly or symptoms in adult ...

Report: RSV-associated Hospitalisation Costs in Singapore Estimated at SGD 9,430 per Patient; Poses Financial Strain on At-risk Older Adults

Report: RSV-associated Hospitalisation Costs in Singapore Estimated at SGD 9,430 per Patient; Poses Financial Strain on At-risk Older Adults

A newly released white paper, based on research conducted independently by IQVIA, a global healthcare consultancy, and commissioned by GSK,...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact Cision

  • General Inquiries
  • Request a Demo
  • Partnerships
  • Media Inquiries

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Careers
  • Accessibility Statement
  • APAC – Simplified Chinese
  • APAC
  • APAC - Traditional Chinese
  • Arabic
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
  • Vietnam

My Services

  • All New Releases
  • Platform

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Platform
[email protected]
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
  • Accessibility
Copyright © 2025 Cision US Inc.